– Breaking through the current limitations
Recombinant antibodies are highly specific detection probes in research, diagnostics, and have emerged over the last two decades as the fastest growing class of therapeutic proteins. Mammalian cell lines, especially the Chinese Hamster ovary (CHO) cell line, represent the most widely used expression systems for the production of these recombinant antibodies.
This is thanks to the capability of CHO cells to produce high quality biologics that can exhibit human-like, post-translational modifications in gram-scale quantities. However, biopharmaceutical production processes utilizing CHO cells still suffer from inherent cellular limitations such as limited growth, low productivity, as well as higher production costs compared to bacteria or yeast based expression systems.
Therefore, Genscript Biotech has sought to address these problems with our novel “TurboCHO™” platform.
Our seminar will present:
- Applications of recombinant antibodies in therapeutic approaches
- Generation of recombinant antibodies via antibody engineering
- Insight into GenScript Biotech’s TurboCHO™ Expression System for recombinant antibody production
Date: Thursday 12th of May 2022
Time: 9:00 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Meeting room: Auditorium
|9:00||Networking, registration and light breakfast|
David Munis Zepernick, Head of Member Engagement and Communication, Medicon Valley Alliance
Michaline Lewicka, Sales Account Manager, GenScript Biotech
|9:40||Therapeutic Recombinant Antibody Development – Breaking through the current limitations|
Monica Zhang, Field Application Scientist, Genscript Biotech
|11:00||End of Good Morning Meeting|
|Monica Zhang, Field Application Scientist, EU division, Genscript Biotech|
With 6 years of immunology and Molecular Biology research experience under her belt, Dr. Monica Zhang works at GenScript Biotech’s European Division as a Field Application Scientist (FAS), supporting our team with her expertise in protein and antibody products.
Before joining GenScript, Dr. Zhang performed research into the role of Protein Arginine Methyltransferases (PRMTs) in the development of atherosclerosis, earning a Ph.D. from the Leiden Academic Centre of Drug Research (LACDR) of Leiden University in the Netherlands.
|Organized by||In collaboration with|